Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
Tissue Regenix Group PLC
TISSUE REGENIX GROUP is a pioneering, international medical technology company, focusing on the development of regenerative products utilising our two platform technologies, dCELL®, addressing soft tissue needs, and BioRinseTM, providing inductive bone allografts.
We are helping to transform the treatment of patients in three key areas: BioSurgery, Orthopaedics & Dental and Cardiac.
| EPIC: | TRX |
| Market: | AIM:TRX |
| 52-week High/Low: | 10.70p / 3.10p |
| Sector: | Pharma & Biotech |
| Market Cap: | £53.38 m |
| Website: | www.tissueregenix.com |
col 3
col 4
col 5
col 6
Big Picture – A Deep Dive Examination of Tissue Regenix Group PLC
Tissue Regenix Group PLC Snapshot
Click here to read more information on our strategy.
BIOSURGERY
Click here for the overview
ORTHOPAEDICS
Click here for the overview
DENTAL
Click here for the overview
CARDIAC
Click here for the overview
Leeds and Texas.
The Board
John Samuel
Non-Executive Chairman
Steve Couldwell
Chief Executive Officer
Gareth Jones
Chief Financial Officer
Alan Miller
Non Executive-Director
Randeep Singh Grewal
Non Executive-Director
Jonathan Glenn
Non-Executive Director
Shervanthi Homer-Vanniasinkam
Non-Executive Director
Significant shareholders
As at 19 February 2019, shareholders holding more than 3% of the share capital of Tissue Regenix Group Plc are:
| Name of Shareholder | % of Voting Rights |
|---|---|
| Invesco Limited | 28.74 |
| Woodford Investment Management LLP | 26.00 |
| Techtran Group Limited | 8.79 |
| Baillie Gifford & Co Ltd | 6.04 |
| Jupiter Asset Management | 5.88 |
| Directors & Related Holdings | 4.28 |
| IP2IPO Limited | 4.27 |
Shares not in public hands as at 19 February 2019 – 856,002,530 - 73%
Shares in issue as at 19 February 2019 - 1,171,730,823 ordinary shares of 0.5p each
The securities of Tissue Regenix Group plc are traded on the AIM market operated by the London Stock Exchange plc. Its shares have not been admitted, nor have any applications been made, for any of its shares to be admitted or traded on any other exchanges or trading platform.
Telephone
+44 (0)330 430 3052
Email
[email protected]
Fax
+44(0)190438517
Investor or Media Enquiries
Caitlin Pearson
Head of Communications
[email protected]
ADDRESS
UK OFFICE
Unit 1 & 2
Astley Way,
Swillington,
Leeds
LS26 8XT
US OFFICE
1808
Universal City Blvd,
Universal City,
Texas
78148
KEY ADVISORS
Nominated Advisor and Broker
STIFEL NICOLAUS EUROPE LIMITED
150 Cheapside,
London,
EC2V 6ET
Auditors
RSM
Central Square,
29 Wellington St,
Leeds
LS1 4DL
Solicitors
DLA PIPER UK LLP
Princes Exchange,
Princes Square,
Leeds,
LS1 4BY
Registrars
CAPITA
4 Beckenham Rd,
Beckenham,
Kent,
BR3 4TU
Videos
Steve Couldwell, chief executive of Tissue Regenix Group PLC (LON:TRX), caught...
Steve Couldwell, chief executive of Tissue Regenix Group PLC (LON:TRX), caught...
Steve Couldwell, chief executive of Tissue Regenix PLC (LON:TRX), tells...
Antony Odell, chief executive of Tissue Regenix PLC (LON:TRX) tells Proactive...
Partners:
